145 related articles for article (PubMed ID: 3162113)
1. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
2. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
3. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1988 Nov; 93(2-3):275-80. PubMed ID: 2907373
[TBL] [Abstract][Full Text] [Related]
4. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Close SP; Marriott AS; Pay S
Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
[TBL] [Abstract][Full Text] [Related]
5. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
6. Effect of D1 receptor stimulation in normal and MPTP monkeys.
Bédard PJ; Boucher R
Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
[TBL] [Abstract][Full Text] [Related]
7. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Elliott PJ; Walsh DM; Close SP
Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609
[TBL] [Abstract][Full Text] [Related]
9. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptors and sensorimotor behavior in MPTP-treated mice.
Weihmuller FB; Hadjiconstantinou M; Bruno JP
Behav Brain Res; 1990 May; 38(3):263-73. PubMed ID: 1973042
[TBL] [Abstract][Full Text] [Related]
12. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Andringa G; Vermeulen RJ; Drukarch B; Stoof JC; Cools AR
Adv Pharmacol; 1998; 42():792-5. PubMed ID: 9328017
[No Abstract] [Full Text] [Related]
14. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Gomez-Mancilla B; Boucher R; Bédard PJ
Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
[TBL] [Abstract][Full Text] [Related]
15. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Ni L
J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Boyce S; Rupniak NM; Steventon MJ; Iversen SD
Neurology; 1990 Jun; 40(6):927-33. PubMed ID: 2140595
[TBL] [Abstract][Full Text] [Related]
17. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
[TBL] [Abstract][Full Text] [Related]
18. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Kuno S
Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
[TBL] [Abstract][Full Text] [Related]
19. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
20. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
